← Back to Search

Small Molecule Drug

AMG 510 for Non-Small Cell Lung Cancer

Phase 1 & 2

Waitlist Available

Led By Wade Iams, MD, MSCI

Research Sponsored by Criterium, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 18.5 months

Awards & highlights

Study Summary

This trial will test a new cancer drug on people with advanced lung cancer that has spread to the brain.

Eligible Conditions

Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 18.5 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~18.5 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 18.5 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose Exploration

Secondary outcome measures

Dose Expansion

Trial Design

1Treatment groups

Experimental Treatment

Group I: Dose ExpansionExperimental Treatment2 Interventions

AMG 510/MVASI

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

AMG 510

2020

Completed Phase 1

~120

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Criterium, Inc.Lead Sponsor

16 Previous Clinical Trials

774 Total Patients Enrolled

AmgenIndustry Sponsor

1,370 Previous Clinical Trials

1,377,688 Total Patients Enrolled

Wade Iams, MD, MSCIPrincipal InvestigatorVanderbilt University Medical Center

Media Library

AMG 510 (Small Molecule Drug) Clinical Trial Eligibility Overview. Trial Name: NCT05180422 — Phase 1 & 2

Non-Small Cell Lung Cancer Research Study Groups: Dose Expansion

Non-Small Cell Lung Cancer Clinical Trial 2023: AMG 510 Highlights & Side Effects. Trial Name: NCT05180422 — Phase 1 & 2

AMG 510 (Small Molecule Drug) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05180422 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the usual applications for AMG 510?

"AMG 510 is a treatment for patients with recurrent non-squamous non-small cell lung cancer, recurrent platinum-sensitive epithelial ovarian cancer, who have had one prior systemic therapy."

Answered by AI

How many participants will this trial have in total?

"The clinical trial is still looking for patients, as detailed on the website clinicaltrials.gov. This specific study was first posted on 6/15/2022 and updated last on 6/28/2022. They are recruiting a total of 43 individuals across 1 site."

Answered by AI

Is AMG 510 a new or experimental drug?

"AMG 510 is being studied in 384 clinical trials, 100 of which are Phase 3. Taibei, Taiwan has several ongoing trials for AMG 510, but there are a total of 20197 locations worldwide where these studies are taking place."

Answered by AI

Are new enrollees still being accepted into the research program?

"The information available on clinicaltrials.gov shows that this trial is looking for more patients as of right now. This particular study was first announced on June 15th, 2022 and has had some updates since then (the most recent being on June 28th, 2022)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

2022. "A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05180422.